ArticleEuropean journal of nuclear medicine and molecular imaging2025
FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidates.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
purposeThe aging liver transplant population presents new challenges in distinguishing irreversible, age-related causes of dementia from hepatic encephalopathy (HE), given their overlapping clinical presentations. Dementia is often assessed through neuropsychological testing (NPT), but imaging utilizing biomarkers like Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) has been considered as an alternative. This preliminary investigation aims to assess FDG PET/CT in screening for irreversible causes of dementia in older liver transplant candidates.
methodsEighteen patients with clinical suspicion for dementia during transplant evaluation were assessed using FDG PET/CT of the brain. Demographic data, FDG PET/CT and NPT results, and time between date of order and interpretation of FDG PET/CT and NPT were collected. Concordance between and time-to-diagnosis of FDG PET/CT and NPT were calculated. FDG PET/CT of these patients were compared to healthy, age-matched controls to determine altered patterns of FDG uptake in the brains of these patients.
results40% of patients were diagnosed with an irreversible cause of dementia on FDG PET/CT. There was moderate agreement (K = 0.44) between NPT and FDG PET/CT. FDG PET/CT had a sensitivity and specificity of 100% and 50%, respectively. Time-to-diagnosis was significantly shorter with FDG PET/CT (12.4 days) compared to NPT (73.1 days). Voxel-wise analysis showed statistically significant diffuse cortical and basal ganglia hypometabolism in patients being evaluated for liver transplant versus age-matched healthy controls.
conclusionFDG PET/CT is helpful in screening for irreversible causes of dementia in older liver transplant candidates, but a positive PET indicates that further evaluation is required before denying a patient a potentially life-saving treatment. Efficient workup for these patients is crucial, and FDG PET/CT could provide a sensitive first screening test for dementia in older patients undergoing liver transplant evaluation which can be confirmed with NPT or with more specific biomarkers of neurodegenerative disease. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.